CO6331346A2 - Anticuerpos anti-factor d humanizados, secuencias, composiciones, kit y articulo de fabricacion del mismo - Google Patents
Anticuerpos anti-factor d humanizados, secuencias, composiciones, kit y articulo de fabricacion del mismoInfo
- Publication number
- CO6331346A2 CO6331346A2 CO10145550A CO10145550A CO6331346A2 CO 6331346 A2 CO6331346 A2 CO 6331346A2 CO 10145550 A CO10145550 A CO 10145550A CO 10145550 A CO10145550 A CO 10145550A CO 6331346 A2 CO6331346 A2 CO 6331346A2
- Authority
- CO
- Colombia
- Prior art keywords
- light chain
- amino acid
- factor
- kit
- sequences
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Microbiology (AREA)
- Psychiatry (AREA)
- Transplantation (AREA)
- Hospice & Palliative Care (AREA)
- Cardiology (AREA)
- Ophthalmology & Optometry (AREA)
- Pain & Pain Management (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
1.- Un anticuerpo anti-factor D que comprende HVR de cadena ligera de un anticuerpo de referencia, donde dicho anticuerpo anti-factor D comprende además una sustitución en una o más posiciones de dicho anticuerpo, donde dicho anticuerpo de referencia comprende HVR-1 de cadena ligera que contiene ITSTDIDDDMN (identificador de secuencia n.°: 30), cadena ligera HVR-2 que comprende GGNTLRP (identificador de secuencia n.°: 35) y cadena ligera HVR-3 que comprende LQSDSLPYT (identificador de secuencia n.°: 38) donde dicha sustitución es una o más de las siguientes:(a) el aminoácido de la posición 33 de la cadena ligera es L o I,(b) el aminoácido de la posición 34 de la cadena ligera es A o Q,(c) el aminoácido de la posición 52 de la cadena ligera es S o A, (d) el aminoácido de la posición 104 de la cadena ligera es V, (e) el aminoácido de la posición 1 de la cadena pesada es E;(f) el aminoácido de la posición 99 de la cadena pesada es A o Q, (g) el aminoácido de la posición 100 de la cadena pesada es A o Q.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US4843108P | 2008-04-28 | 2008-04-28 | |
US4868908P | 2008-04-29 | 2008-04-29 |
Publications (1)
Publication Number | Publication Date |
---|---|
CO6331346A2 true CO6331346A2 (es) | 2011-10-20 |
Family
ID=40999836
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CO10145550A CO6331346A2 (es) | 2008-04-28 | 2010-11-19 | Anticuerpos anti-factor d humanizados, secuencias, composiciones, kit y articulo de fabricacion del mismo |
Country Status (35)
Country | Link |
---|---|
US (7) | US8273352B2 (es) |
EP (3) | EP3235829B1 (es) |
JP (2) | JP5636359B2 (es) |
KR (2) | KR101322027B1 (es) |
CN (2) | CN103724433B (es) |
AR (2) | AR071510A1 (es) |
AU (1) | AU2009241348C1 (es) |
BR (1) | BRPI0907701A2 (es) |
CA (2) | CA2720853C (es) |
CL (2) | CL2009001001A1 (es) |
CO (1) | CO6331346A2 (es) |
CR (2) | CR20170001A (es) |
CY (1) | CY1116982T1 (es) |
DK (1) | DK2283041T3 (es) |
EC (1) | ECSP10010637A (es) |
ES (1) | ES2552817T3 (es) |
HK (3) | HK1147503A1 (es) |
HR (1) | HRP20151259T1 (es) |
HU (1) | HUE026349T2 (es) |
IL (3) | IL208555A (es) |
MA (1) | MA32300B1 (es) |
MX (2) | MX2010011342A (es) |
MY (1) | MY162350A (es) |
NZ (3) | NZ603492A (es) |
PE (2) | PE20091783A1 (es) |
PH (1) | PH12014500519A1 (es) |
PL (1) | PL2283041T3 (es) |
PT (1) | PT2283041E (es) |
RS (1) | RS54405B1 (es) |
RU (1) | RU2488594C2 (es) |
SG (2) | SG189756A1 (es) |
SI (1) | SI2283041T1 (es) |
TW (3) | TWI558413B (es) |
WO (1) | WO2009134711A1 (es) |
ZA (1) | ZA201301709B (es) |
Families Citing this family (44)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007056227A2 (en) * | 2005-11-04 | 2007-05-18 | Genentech, Inc. | Use of complement pathway inhibitors to treat ocular diseases |
DK1976877T4 (en) | 2005-11-30 | 2017-01-16 | Abbvie Inc | Monoclonal antibodies to amyloid beta protein and uses thereof |
PT1954718E (pt) | 2005-11-30 | 2014-12-16 | Abbvie Inc | Anticorpos anti-globulómeros aβ, suas porções de ligação ao antigénio, correspondentes hibridomas, ácidos nucleicos, vectores, células hospedeiras, métodos de produção dos ditos anticorpos, composições compreendendo os ditos anticorpos, usos dos ditos anticorpos e métodos para uso dos ditos anticorpos |
EP2097455B1 (en) | 2006-11-02 | 2014-10-22 | Genentech, Inc. | Humanized anti-factor d antibodies |
US8455626B2 (en) | 2006-11-30 | 2013-06-04 | Abbott Laboratories | Aβ conformer selective anti-aβ globulomer monoclonal antibodies |
CR20170001A (es) * | 2008-04-28 | 2017-08-10 | Genentech Inc | Anticuerpos anti factor d humanizados |
US20110165648A1 (en) * | 2009-11-04 | 2011-07-07 | Menno Van Lookeren Campagne | Co-crystal structure of factor D and anti-factor D antibody |
MX360403B (es) | 2010-04-15 | 2018-10-31 | Abbvie Inc | Proteinas de union a amiloide beta. |
EP2603524A1 (en) | 2010-08-14 | 2013-06-19 | AbbVie Inc. | Amyloid-beta binding proteins |
US9732143B2 (en) * | 2011-02-03 | 2017-08-15 | Xoma Technology Ltd. | Methods and materials for enhancing functional protein expression in bacteria |
EP2689326B1 (en) | 2011-03-25 | 2022-11-16 | Intel Corporation | Memory fragments for supporting code block execution by using virtual cores instantiated by partitionable engines |
WO2013077876A1 (en) * | 2011-11-22 | 2013-05-30 | Soft Machines, Inc. | A microprocessor accelerated code optimizer |
US20140081003A1 (en) | 2012-09-19 | 2014-03-20 | Genentech, Inc. | Methods and compositions for preventing norleucine misincorporation into proteins |
CA2891686A1 (en) | 2012-12-18 | 2014-06-26 | Novartis Ag | Compositions and methods that utilize a peptide tag that binds to hyaluronan |
EP2970453B1 (en) | 2013-03-13 | 2019-12-04 | Prothena Biosciences Limited | Tau immunotherapy |
CN105247484B (zh) | 2013-03-15 | 2021-02-23 | 英特尔公司 | 利用本地分布式标志体系架构来仿真访客集中式标志体系架构的方法 |
WO2014197885A2 (en) | 2013-06-07 | 2014-12-11 | Duke University | Inhibitors of complement factor h |
KR20160042438A (ko) * | 2013-08-12 | 2016-04-19 | 제넨테크, 인크. | 보체-연관 상태의 치료를 위한 조성물 및 방법 |
EP3054965B1 (en) * | 2013-10-07 | 2021-04-14 | Massachusetts Eye & Ear Infirmary | Anti-factor d antibody for use in preventing or reducing retinal detachment |
US10179821B2 (en) | 2014-05-01 | 2019-01-15 | Genentech, Inc. | Anti-factor D antibodies |
WO2015198240A2 (en) | 2014-06-25 | 2015-12-30 | Novartis Ag | Compositions and methods for long acting proteins |
WO2015198243A2 (en) | 2014-06-25 | 2015-12-30 | Novartis Ag | Compositions and methods for long acting proteins |
US9840553B2 (en) | 2014-06-28 | 2017-12-12 | Kodiak Sciences Inc. | Dual PDGF/VEGF antagonists |
AU2016344133A1 (en) * | 2015-10-30 | 2018-05-17 | Genentech, Inc. | Anti-Factor D antibody formulations |
WO2017075173A2 (en) * | 2015-10-30 | 2017-05-04 | Genentech, Inc. | Anti-factor d antibodies and conjugates |
CN108513585A (zh) | 2015-10-30 | 2018-09-07 | 豪夫迈·罗氏有限公司 | 测量因子d活性和因子d抑制剂效力的方法 |
CA3001362C (en) | 2015-10-30 | 2020-10-13 | Genentech, Inc. | Anti-htra1 antibodies and methods of use thereof |
PL3368579T3 (pl) * | 2015-10-30 | 2022-03-21 | F. Hoffmann-La Roche Ag | Fragmenty przeciwciał ze zmodyfikowanymi regionami zawiasowymi i sposoby ich wytwarzania |
US10654932B2 (en) | 2015-10-30 | 2020-05-19 | Genentech, Inc. | Anti-factor D antibody variant conjugates and uses thereof |
US10723788B2 (en) * | 2015-11-24 | 2020-07-28 | Annexon, Inc. | Anti-complement factor C1q Fab fragments and uses thereof |
IL290457B1 (en) | 2015-12-30 | 2024-10-01 | Kodiak Sciences Inc | Antibodies and their conjugates |
JP2019506159A (ja) * | 2016-01-20 | 2019-03-07 | ヴィトリサ セラピューティクス, インコーポレイテッド | D因子を阻害するための組成物および方法 |
CN107043422B (zh) * | 2016-01-28 | 2022-01-04 | 成都康弘生物科技有限公司 | 抗补体因子D的人源化Fab和人源化抗体及其用途 |
WO2017191559A1 (en) * | 2016-05-02 | 2017-11-09 | Prothena Biosciences Limited | Tau immunotherapy |
WO2018136827A1 (en) | 2017-01-20 | 2018-07-26 | Vitrisa Therapeutics, Inc. | Stem-loop compositions and methods for inhibiting factor d |
EA201991876A1 (ru) | 2017-02-10 | 2020-03-13 | Дзе Трастиз Оф Дзе Юниверсити Оф Пенсильвания | Антитела против фактора d и их применения |
CN106905431B (zh) * | 2017-04-10 | 2020-01-17 | 旭华(上海)生物研发中心有限公司 | 抗人补体d因子的单克隆抗体及其用途 |
WO2018191548A2 (en) | 2017-04-14 | 2018-10-18 | Kodiak Sciences Inc. | Complement factor d antagonist antibodies and conjugates thereof |
IL270375B1 (en) | 2017-05-02 | 2024-08-01 | Prothena Biosciences Ltd | Antibodies that recognize tau |
US10865238B1 (en) | 2017-05-05 | 2020-12-15 | Duke University | Complement factor H antibodies |
GB201800620D0 (en) | 2018-01-15 | 2018-02-28 | Univ Manchester | C3b Binding Polypeptide |
MX2020009152A (es) | 2018-03-02 | 2020-11-09 | Kodiak Sciences Inc | Anticuerpos de il-6 y constructos de fusion y conjugados de los mismos. |
EP3608674A1 (en) * | 2018-08-09 | 2020-02-12 | Regeneron Pharmaceuticals, Inc. | Methods for assessing binding affinity of an antibody variant to the neonatal fc receptor |
CA3157509A1 (en) | 2019-10-10 | 2021-04-15 | Kodiak Sciences Inc. | Methods of treating an eye disorder |
Family Cites Families (104)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
US4399216A (en) | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
US4376110A (en) | 1980-08-04 | 1983-03-08 | Hybritech, Incorporated | Immunometric assays using monoclonal antibodies |
US4560655A (en) | 1982-12-16 | 1985-12-24 | Immunex Corporation | Serum-free cell culture medium and process for making same |
US4657866A (en) | 1982-12-21 | 1987-04-14 | Sudhir Kumar | Serum-free, synthetic, completely chemically defined tissue culture media |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
DD266710A3 (de) | 1983-06-06 | 1989-04-12 | Ve Forschungszentrum Biotechnologie | Verfahren zur biotechnischen Herstellung van alkalischer Phosphatase |
US4767704A (en) | 1983-10-07 | 1988-08-30 | Columbia University In The City Of New York | Protein-free culture medium |
US4737456A (en) | 1985-05-09 | 1988-04-12 | Syntex (U.S.A.) Inc. | Reducing interference in ligand-receptor binding assays |
GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
US4946783A (en) | 1987-01-30 | 1990-08-07 | President And Fellows Of Harvard College | Periplasmic protease mutants of Escherichia coli |
US5010182A (en) | 1987-07-28 | 1991-04-23 | Chiron Corporation | DNA constructs containing a Kluyveromyces alpha factor leader sequence for directing secretion of heterologous polypeptides |
DE3889546T2 (de) | 1987-12-21 | 1994-09-08 | Univ Toledo | Transformation von keimenden pflanzensamen mit hilfe von agrobacterium. |
US5256642A (en) | 1988-04-01 | 1993-10-26 | The Johns Hopkins University | Compositions of soluble complement receptor 1 (CR1) and a thrombolytic agent, and the methods of use thereof |
AU4005289A (en) | 1988-08-25 | 1990-03-01 | Smithkline Beecham Corporation | Recombinant saccharomyces |
US6048728A (en) | 1988-09-23 | 2000-04-11 | Chiron Corporation | Cell culture medium for enhanced cell growth, culture longevity, and product expression |
NZ230747A (en) | 1988-09-30 | 1992-05-26 | Bror Morein | Immunomodulating matrix comprising a complex of at least one lipid and at least one saponin; certain glycosylated triterpenoid saponins derived from quillaja saponaria molina |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
FR2646437B1 (fr) | 1989-04-28 | 1991-08-30 | Transgene Sa | Nouvelles sequences d'adn, leur application en tant que sequence codant pour un peptide signal pour la secretion de proteines matures par des levures recombinantes, cassettes d'expression, levures transformees et procede de preparation de proteines correspondant |
CA2018228C (en) | 1989-06-05 | 1996-02-27 | Nancy L. Parenteau | Cell culture systems and media |
US5122469A (en) | 1990-10-03 | 1992-06-16 | Genentech, Inc. | Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins |
US5508192A (en) | 1990-11-09 | 1996-04-16 | Board Of Regents, The University Of Texas System | Bacterial host strains for producing proteolytically sensitive polypeptides |
US5264365A (en) | 1990-11-09 | 1993-11-23 | Board Of Regents, The University Of Texas System | Protease-deficient bacterial strains for production of proteolytically sensitive polypeptides |
WO1992022653A1 (en) * | 1991-06-14 | 1992-12-23 | Genentech, Inc. | Method for making humanized antibodies |
US7018809B1 (en) | 1991-09-19 | 2006-03-28 | Genentech, Inc. | Expression of functional antibody fragments |
US5456909A (en) | 1992-08-07 | 1995-10-10 | T Cell Sciences, Inc. | Glycoform fractions of recombinant soluble complement receptor 1 (sCR1) having extended half-lives in vivo |
JPH08500826A (ja) | 1992-08-21 | 1996-01-30 | ジェネンテク,インコーポレイテッド | Lfa−1仲介疾患を処置する方法 |
US5861156A (en) | 1993-01-08 | 1999-01-19 | Creative Biomolecules | Methods of delivering agents to target cells |
US5856300A (en) | 1994-05-12 | 1999-01-05 | T Cell Sciences, Inc. | Compositions comprising complement related proteins and carbohydrates, and methods for producing and using said compositions |
US5679546A (en) | 1993-09-24 | 1997-10-21 | Cytomed, Inc. | Chimeric proteins which block complement activation |
US5627264A (en) | 1994-03-03 | 1997-05-06 | Alexion Pharmaceuticals, Inc. | Chimeric complement inhibitor proteins |
AU2191795A (en) | 1994-03-23 | 1995-10-09 | Alexion Pharmaceuticals, Inc. | Method for reducing immune and hemostatic dysfunctions during extracorporeal circulation |
US5534615A (en) | 1994-04-25 | 1996-07-09 | Genentech, Inc. | Cardiac hypertrophy factor and uses therefor |
US6074642A (en) | 1994-05-02 | 2000-06-13 | Alexion Pharmaceuticals, Inc. | Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis |
US5679345A (en) | 1994-06-02 | 1997-10-21 | The Johns Hopkins University | Method for preventing complement-dependent rejection of organ or tissue transplants |
WO2000053758A2 (en) | 1999-03-08 | 2000-09-14 | Genentech, Inc. | Compositions and methods for the treatment of immune related diseases |
US5679564A (en) | 1994-10-05 | 1997-10-21 | Antex Biologics, Inc. | Methods for producing enhanced antigenic campylobacter bacteria and vaccines |
US5789199A (en) | 1994-11-03 | 1998-08-04 | Genentech, Inc. | Process for bacterial production of polypeptides |
US5639635A (en) | 1994-11-03 | 1997-06-17 | Genentech, Inc. | Process for bacterial production of polypeptides |
US5840523A (en) | 1995-03-01 | 1998-11-24 | Genetech, Inc. | Methods and compositions for secretion of heterologous polypeptides |
AU2660397A (en) | 1996-04-05 | 1997-10-29 | Board Of Regents, The University Of Texas System | Methods for producing soluble, biologically-active disulfide bond-containing eukaryotic proteins in bacterial cells |
US20050197285A1 (en) | 1997-03-07 | 2005-09-08 | Rosen Craig A. | Human secreted proteins |
WO2001036432A2 (en) | 1999-11-19 | 2001-05-25 | Human Genome Sciences, Inc. | 18 human secreted proteins |
US6472520B2 (en) | 1997-03-21 | 2002-10-29 | The Trustees Of Columbia University In The City Of New York | Rat PEG-3 promoter |
US6083715A (en) | 1997-06-09 | 2000-07-04 | Board Of Regents, The University Of Texas System | Methods for producing heterologous disulfide bond-containing polypeptides in bacterial cells |
US6410708B1 (en) | 1997-11-21 | 2002-06-25 | Genentech, Inc. | Nucleic acids encoding A-33 related antigen polypeptides |
ATE335511T1 (de) | 1997-08-26 | 2006-09-15 | Amgen Fremont Inc | Ein verfahren zur inhibierung der komplementaktivierung über einen alternativen weg |
US7419663B2 (en) | 1998-03-20 | 2008-09-02 | Genentech, Inc. | Treatment of complement-associated disorders |
US8007798B2 (en) | 1997-11-21 | 2011-08-30 | Genentech, Inc. | Treatment of complement-associated disorders |
US7192589B2 (en) | 1998-09-16 | 2007-03-20 | Genentech, Inc. | Treatment of inflammatory disorders with STIgMA immunoadhesins |
US7282565B2 (en) | 1998-03-20 | 2007-10-16 | Genentech, Inc. | PRO362 polypeptides |
EP1481990B1 (en) | 1997-11-21 | 2007-06-06 | Genentech, Inc. | A-33 related antigens and their pharmacological uses |
US8088386B2 (en) | 1998-03-20 | 2012-01-03 | Genentech, Inc. | Treatment of complement-associated disorders |
CA2320625A1 (en) | 1998-02-09 | 1999-08-12 | Human Genome Sciences, Inc. | 45 human secreted proteins |
US6956107B2 (en) * | 1998-02-20 | 2005-10-18 | Tanox, Inc. | Inhibitors of complement activation |
US7112327B2 (en) | 1998-02-20 | 2006-09-26 | Tanox, Inc. | Inhibition of complement activation |
CA2321140C (en) | 1998-02-20 | 2015-04-07 | Tanox, Inc. | Inhibitors of complement activation |
ES2312205T3 (es) | 1998-03-10 | 2009-02-16 | Genentech, Inc. | Nuevo polipeptido y acidos nucleicos que lo codifican. |
JP2002523089A (ja) | 1998-08-27 | 2002-07-30 | インサイト・ファーマスーティカルズ・インコーポレイテッド | タンパク質輸送関連分子 |
EP1141285A2 (en) | 1998-12-16 | 2001-10-10 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
MXPA01006330A (es) | 1998-12-22 | 2002-07-02 | Genentech Inc | Metodos y composiciones para inhibir el crecimiento de celulas neoplasticas. |
KR20060067983A (ko) | 1999-01-15 | 2006-06-20 | 제넨테크, 인크. | 효과기 기능이 변화된 폴리펩티드 변이체 |
DE60045681D1 (de) | 1999-03-11 | 2011-04-14 | Merck Serono Sa | Vaskuläre adhesionsmoleküle und modulierung ihrer funktion |
US6642353B1 (en) | 1999-03-17 | 2003-11-04 | Chugai Seiyaku Kabushiki Kaisha | Peptide ligands for the erythropoietin receptor |
AU2883900A (en) | 1999-07-07 | 2001-01-30 | Genentech Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
CA2490909A1 (en) | 1999-12-01 | 2001-06-07 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
US6821775B1 (en) | 2000-02-11 | 2004-11-23 | Genvec, Inc. | Viral vector encoding pigment epithelium-derived factor |
AU2001249410A1 (en) | 2000-03-23 | 2001-10-03 | Tanox, Inc. | Anti-c2/c2a inhibitors of complement activation |
ATE412185T1 (de) | 2000-04-29 | 2008-11-15 | Univ Iowa Res Found | Diagnostika und therapeutika für makula degeneration erkrankungen |
EP1309620A2 (en) | 2000-06-23 | 2003-05-14 | Genentech, Inc. | Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis |
CA2416538A1 (en) | 2000-07-20 | 2002-01-31 | Genentech, Inc. | Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis |
EP2113516B1 (en) | 2000-10-10 | 2014-05-21 | Genentech, Inc. | Antibodies against C5 inhibiting type II endothelial cell activation |
CN1547590A (zh) | 2000-10-13 | 2004-11-17 | ¸ | 人源化抗-LT-β-R抗体 |
US20040077575A1 (en) | 2002-01-11 | 2004-04-22 | Giordano Giovan Giacomo | Inhibition of pathological angiogenesis in vivo |
US7432356B2 (en) | 2001-08-17 | 2008-10-07 | Genentech, Inc. | Complement pathway inhibitors binding to C5 and C5a without preventing formation of C5b |
AR040778A1 (es) * | 2002-08-06 | 2005-04-20 | Glaxo Group Ltd | Anticuerpos alterados o fragmentos funcionales que se unen a mag (glicoproteina asociada a mielina). |
WO2004022594A2 (en) | 2002-09-06 | 2004-03-18 | Cytos Biotechnology Ag | Immune modulatory compounds and methods |
US7816497B2 (en) | 2002-10-30 | 2010-10-19 | University Of Kentucky | Compositions and methods for inhibiting drusen complement components C3a and C5a for the treatment of age-related macular degeneration |
RU2232991C1 (ru) | 2003-04-09 | 2004-07-20 | Государственное учреждение "Московский научно-исследовательский институт эпидемиологии и микробиологии им. Г.Н. Габричевского" | Способ определения функциональной активности фактора d комплемента человека |
US7709610B2 (en) * | 2003-05-08 | 2010-05-04 | Facet Biotech Corporation | Therapeutic use of anti-CS1 antibodies |
WO2005014849A2 (en) | 2003-07-03 | 2005-02-17 | Euro-Celtique, S.A. | Genes associated with responses to neuropathic pain |
WO2005025509A2 (en) | 2003-09-11 | 2005-03-24 | Board Of Regents, The University Of Texas System | Methods and materials for treating autoimmune diseases and conditions |
US20050169921A1 (en) * | 2004-02-03 | 2005-08-04 | Leonard Bell | Method of treating hemolytic disease |
US7127355B2 (en) | 2004-03-05 | 2006-10-24 | Perlegen Sciences, Inc. | Methods for genetic analysis |
US7794713B2 (en) * | 2004-04-07 | 2010-09-14 | Lpath, Inc. | Compositions and methods for the treatment and prevention of hyperproliferative diseases |
AU2005314461B2 (en) | 2004-11-18 | 2012-02-02 | The Rockefeller University | Methods and compositions for treating ocular disorders |
WO2006071856A2 (en) | 2004-12-23 | 2006-07-06 | Glycofi, Inc. | Immunoglobulins comprising predominantly a man5glcnac2 glycoform |
WO2006088950A2 (en) | 2005-02-14 | 2006-08-24 | University Of Iowa Research Foundation | Methods and reagents for treatment and diagnosis of age-related macular degeneration |
EP1907576B1 (en) | 2005-06-08 | 2014-07-23 | University of Pittsburgh of the Commonwealth System of Higher Education | SUSCEPTIBILITY GENES FOR AGE-RELATED MACULOPATHY (ARM) ON CHROMOSOME 10q26 |
PL1951279T3 (pl) | 2005-10-08 | 2017-12-29 | Apellis Pharmaceuticals, Inc. | Kompstatyna i jej analogi w zaburzeniach oczu |
WO2007056227A2 (en) * | 2005-11-04 | 2007-05-18 | Genentech, Inc. | Use of complement pathway inhibitors to treat ocular diseases |
US20070190057A1 (en) | 2006-01-23 | 2007-08-16 | Jian Wu | Methods for modulating mannose content of recombinant proteins |
EP2097455B1 (en) | 2006-11-02 | 2014-10-22 | Genentech, Inc. | Humanized anti-factor d antibodies |
US20090111708A1 (en) | 2007-05-11 | 2009-04-30 | Seddon Johanna M | Polynucleotides associated with age-related macular degeneration and methods for evaluating patient risk |
AR066660A1 (es) * | 2007-05-23 | 2009-09-02 | Genentech Inc | Prevencion y tratamiento de condiciones del ojo asociadas con su complemento |
AU2009251499B2 (en) | 2008-04-18 | 2015-07-16 | The General Hospital Corporation | Polymorphisms associated with age-related macular degeneration and methods for evaluating patient risk |
CR20170001A (es) | 2008-04-28 | 2017-08-10 | Genentech Inc | Anticuerpos anti factor d humanizados |
US20120003641A1 (en) | 2008-11-05 | 2012-01-05 | Graham Robert R | Genetic polymorphisms in age-related macular degeneration |
WO2010075519A2 (en) | 2008-12-23 | 2010-07-01 | Massachusetts Eye & Ear Infirmary | Allelic variants associated with advanced age-related macular degeneration |
WO2010085542A2 (en) | 2009-01-23 | 2010-07-29 | Novartis Ag | Biomarkers related to age-related macular degeneration (amd) |
US20110165648A1 (en) * | 2009-11-04 | 2011-07-07 | Menno Van Lookeren Campagne | Co-crystal structure of factor D and anti-factor D antibody |
JP5651527B2 (ja) * | 2011-05-02 | 2015-01-14 | 沖電気工業株式会社 | 無線端末装置、無線通信システム、プログラムおよび無線通信方法 |
-
2009
- 2009-03-27 CR CR20170001A patent/CR20170001A/es unknown
- 2009-04-27 ES ES09739513.1T patent/ES2552817T3/es active Active
- 2009-04-27 TW TW098113922A patent/TWI558413B/zh not_active IP Right Cessation
- 2009-04-27 DK DK09739513.1T patent/DK2283041T3/da active
- 2009-04-27 US US12/430,479 patent/US8273352B2/en not_active Expired - Fee Related
- 2009-04-27 HU HUE09739513A patent/HUE026349T2/en unknown
- 2009-04-27 PL PL09739513T patent/PL2283041T3/pl unknown
- 2009-04-27 AU AU2009241348A patent/AU2009241348C1/en not_active Ceased
- 2009-04-27 SG SG2013025630A patent/SG189756A1/en unknown
- 2009-04-27 RS RS20150745A patent/RS54405B1/en unknown
- 2009-04-27 CL CL2009001001A patent/CL2009001001A1/es unknown
- 2009-04-27 EP EP17157837.0A patent/EP3235829B1/en active Active
- 2009-04-27 KR KR1020107026550A patent/KR101322027B1/ko active IP Right Review Request
- 2009-04-27 CN CN201310681246.5A patent/CN103724433B/zh not_active Expired - Fee Related
- 2009-04-27 JP JP2011507553A patent/JP5636359B2/ja not_active Expired - Fee Related
- 2009-04-27 TW TW103106291A patent/TWI616456B/zh not_active IP Right Cessation
- 2009-04-27 PT PT97395131T patent/PT2283041E/pt unknown
- 2009-04-27 BR BRPI0907701 patent/BRPI0907701A2/pt not_active Application Discontinuation
- 2009-04-27 CN CN200980123668.2A patent/CN102066419B/zh not_active Expired - Fee Related
- 2009-04-27 NZ NZ603492A patent/NZ603492A/en not_active IP Right Cessation
- 2009-04-27 EP EP15178110.1A patent/EP3002295A1/en not_active Withdrawn
- 2009-04-27 WO PCT/US2009/041785 patent/WO2009134711A1/en active Application Filing
- 2009-04-27 CA CA2720853A patent/CA2720853C/en not_active Expired - Fee Related
- 2009-04-27 SI SI200931308T patent/SI2283041T1/sl unknown
- 2009-04-27 TW TW106129777A patent/TW201819418A/zh unknown
- 2009-04-27 KR KR1020137017779A patent/KR20130084330A/ko not_active Application Discontinuation
- 2009-04-27 CA CA2908470A patent/CA2908470A1/en not_active Abandoned
- 2009-04-27 PE PE2009000572A patent/PE20091783A1/es active IP Right Grant
- 2009-04-27 RU RU2010148423/10A patent/RU2488594C2/ru not_active IP Right Cessation
- 2009-04-27 NZ NZ621103A patent/NZ621103A/en not_active IP Right Cessation
- 2009-04-27 MX MX2010011342A patent/MX2010011342A/es active IP Right Grant
- 2009-04-27 NZ NZ588457A patent/NZ588457A/xx not_active IP Right Cessation
- 2009-04-27 MY MYPI2010004883A patent/MY162350A/en unknown
- 2009-04-27 PE PE2013002736A patent/PE20140806A1/es active IP Right Grant
- 2009-04-27 EP EP09739513.1A patent/EP2283041B1/en active Active
- 2009-04-27 AR ARP090101490A patent/AR071510A1/es active IP Right Grant
- 2009-04-27 SG SG10201608305SA patent/SG10201608305SA/en unknown
-
2010
- 2010-10-07 IL IL208555A patent/IL208555A/en active IP Right Grant
- 2010-10-15 MX MX2018013087A patent/MX2018013087A/es unknown
- 2010-11-11 MA MA33342A patent/MA32300B1/fr unknown
- 2010-11-19 CO CO10145550A patent/CO6331346A2/es active IP Right Grant
- 2010-11-26 EC EC2010010637A patent/ECSP10010637A/es unknown
- 2010-11-26 CR CR11817A patent/CR11817A/es unknown
-
2011
- 2011-02-17 HK HK11101560.5A patent/HK1147503A1/xx not_active IP Right Cessation
-
2012
- 2012-05-04 AR ARP120101576A patent/AR086272A2/es unknown
- 2012-08-22 US US13/591,755 patent/US8614306B2/en not_active Expired - Fee Related
-
2013
- 2013-03-06 ZA ZA2013/01709A patent/ZA201301709B/en unknown
- 2013-06-18 JP JP2013128011A patent/JP5931008B2/ja not_active Expired - Fee Related
- 2013-09-20 US US14/033,175 patent/US9676868B2/en not_active Expired - Fee Related
-
2014
- 2014-03-05 US US14/198,021 patent/US20140212433A1/en not_active Abandoned
- 2014-03-07 PH PH12014500519A patent/PH12014500519A1/en unknown
- 2014-06-27 HK HK14106480.8A patent/HK1193111A1/zh not_active IP Right Cessation
-
2015
- 2015-11-23 US US14/948,911 patent/US20160145349A1/en not_active Abandoned
- 2015-11-23 HR HRP20151259TT patent/HRP20151259T1/hr unknown
- 2015-11-26 CY CY20151101079T patent/CY1116982T1/el unknown
-
2017
- 2017-05-18 US US15/598,735 patent/US20180100024A1/en not_active Abandoned
- 2017-06-19 IL IL253014A patent/IL253014A0/en unknown
-
2018
- 2018-02-28 CL CL2018000537A patent/CL2018000537A1/es unknown
- 2018-04-25 HK HK18105422.7A patent/HK1245812A1/zh unknown
- 2018-07-27 US US16/048,002 patent/US20190185579A1/en not_active Abandoned
-
2019
- 2019-04-15 IL IL266039A patent/IL266039A/en unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CO6331346A2 (es) | Anticuerpos anti-factor d humanizados, secuencias, composiciones, kit y articulo de fabricacion del mismo | |
PE20110306A1 (es) | Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) | |
PE20120340A1 (es) | Combinaciones antitumorales que contienen anticuerpos que reconocen especificamente cd38 y melfalan | |
CO6190543A2 (es) | Anticuerpos anti-factor d humanizados | |
CO6700829A2 (es) | Moduladores novedosos y métodos de uso | |
CO5720212A1 (es) | Composicion de anticuerpo her2 | |
PE20181805A1 (es) | Composiciones y anticuerpos anti-tim-3 | |
CY1118007T1 (el) | Μεθοδοι για την χορηγηση υπογλυκαιμικων μεσων | |
RS54133B1 (en) | ANTI-IL-6 ANTIBODIES, PREPARATIONS, PREPARATION AND USE PROCEDURES | |
RS54468B1 (en) | MONOCLONAL ANTIBODIES AGAINST CLAUDINE-18 FOR THE CANCER TREATMENT | |
PE20181921A1 (es) | NUEVOS ANTICUERPOS ANTI-SIRPa Y SUS APLICACIONES TERAPEUTICAS | |
CO6230999A2 (es) | Anticuerpo anti-esclerostina | |
ES2685823T3 (es) | Anticuerpos antagonistas anti-CD40 | |
PE20120816A1 (es) | Composiciones que comprenden anticuerpos de dickkopf-1 | |
EA200802170A1 (ru) | Лиофилизированная композиция терапевтического пептидного антитела | |
ES2721753T3 (es) | Anticuerpos contra IL-6 y usos de los mismos | |
ES2585480T3 (es) | Anticuerpo anti-NR10 y uso del mismo | |
PE20130817A1 (es) | Anticuerpos peptidicos beta amiloide anti-n3pglu y usos de los mismos | |
PE20120205A1 (es) | Combinaciones antitumorales que contienen anticuerpos que reconocen especificamente cd38 y citarabina | |
CO6260094A2 (es) | Anticuerpos novedosos anti-alpha5beta1 y usos de los mismos | |
CR10563A (es) | Anticuerpos monoclonales ant-il-6 y usos de los mismos | |
PE20140882A1 (es) | Anticuerpos neutralizantes de citomegalovirus humano | |
PE20120429A1 (es) | Proteinas de enlace de miostatina | |
RS53685B1 (en) | HUMAN ANTI-IL-23 ANTIBODIES, COMPOSITIONS, METHODS AND APPLICATIONS | |
PE20080739A1 (es) | Anticuerpos para il-17a |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Application granted |